Parkinson's DiseaseDuring the premarketing development of ropinirole hydrochloride,
patients received ropinirole hydrochloride either without L-dopa (early
Parkinson's disease studies) or as concomitant therapy with L-dopa (advanced
Parkinson's disease studies). Because these two populations may have
differential risks for various adverse events, this section will, in general,
present adverse event data for these two populations separately.
Early Parkinson's Disease (Without L-dopa)
The most commonly observed adverse events (>5%) in the
double-blind, placebo-controlled early Parkinson's disease trials associated
with the use of ropinirole hydrochloride (n = 157) not seen at an equivalent
frequency among the placebo-treated patients (n = 147) were, in order of
decreasing incidence: nausea, dizziness, somnolence, headache, vomiting,
syncope, fatigue, dyspepsia, viral infection, constipation, pain, increased
sweating, asthenia, dependent/leg edema, orthostatic symptoms, abdominal pain,
pharyngitis, confusion, hallucinations, urinary tract infections, and abnormal
vision.
Approximately 24% of 157 patients treated with ropinirole hydrochloride who
participated in the double-blind, placebo-controlled early Parkinson's disease
(without L-dopa) trials discontinued treatment due to adverse events compared to
13% of 147 patients who received placebo. The adverse events most commonly
causing discontinuation of treatment by patients treated with ropinirole
hydrochloride were: nausea (6.4%), dizziness (3.8%), aggravated Parkinson's
disease (1.3%), hallucinations (1.3%), somnolence (1.3%), vomiting (1.3%), and
headache (1.3%). Of these, hallucinations appear to be dose related. While other
adverse events leading to discontinuation may be dose related, the titration
design utilized in these trials precluded an adequate assessment of the dose
response. For example, in the larger of the two trials described in CLINICAL
PHARMACOLOGY: Clinical Trials, the difference in the rate of discontinuations
emerged only after 10 weeks of treatment, suggesting, although not proving, that
the effect could be related to dose.
Adverse Event Incidence in Controlled Clinical
Studies
Table 2 lists treatment-emergent adverse events that occurred in
≥2% of patients with early Parkinson's disease (without L-dopa) treated with
ropinirole hydrochloride participating in the double-blind, placebo-controlled
studies and were numerically more common in the group treated with ropinirole
hydrochloride. In these studies, either ropinirole hydrochloride or placebo was
used as early therapy (i.e., without L-dopa).
The prescriber should be aware that these figures cannot be used to predict
the incidence of adverse events in the course of usual medical practice where
patient characteristics and other factors differ from those that prevailed in
the clinical studies. Similarly, the cited frequencies cannot be compared with
figures obtained from other clinical investigations involving different
treatments, uses, and investigators. However, the cited figures do provide the
prescribing physician with some basis for estimating the relative contribution
of drug and non-drug factors to the adverse-events incidence rate in the
population studied.
Table 2. Treatment-Emergent Adverse Event * Incidence in Double-Blind, Placebo-Controlled
Early Parkinson's Disease (Without L-dopa) Trials (Events ≥2% of Patients
Treated With Ropinirole and Numerically More Frequent Than the Placebo Group)
| Adverse Experience | Ropinirole (n = 157) (%) | Placebo (n =
147) (%) |
| Autonomic nervous
system |
|
|
| Flushing | 3 | 1 |
| Dry mouth | 5 | 3 |
| Increased sweating | 6 | 4 |
| Body as a whole |
|
|
| Asthenia | 6 | 1 |
| Chest Pain | 4 | 2 |
| Dependent edema | 6 | 3 |
| Leg edema | 7 | 1 |
| Fatigue | 11 | 4 |
| Malaise | 3 | 1 |
| Pain | 8 | 4 |
| Cardiovascular general |
|
|
| Hypertension | 5 | 3 |
| Hypotension | 2 | 0 |
| Orthostatic symptoms | 6 | 5 |
| Syncope | 12 | 1 |
| Central/peripheral nervous
system |
|
|
| Dizziness | 40 | 22 |
| Hyperkinesia | 2 | 1 |
| Hypesthesia | 4 | 2 |
| Vertigo | 2 | 0 |
| Gastrointestinal system |
|
|
| Abdominal pain | 6 | 3 |
| Anorexia | 4 | 1 |
| Dyspepsia | 10 | 5 |
| Flatulence | 3 | 1 |
| Nausea | 60 | 22 |
| Vomiting | 12 | 7 |
| Heart rate/rhythm |
|
|
| Extrasystoles | 2 | 1 |
| Atrial fibrillation | 2 | 0 |
| Palpitation | 3 | 2 |
| Tachycardia | 2 | 0 |
| Metabolic/nutritional |
|
|
| Increased alkaline
phosphatase | 3 | 1 |
| Psychiatric |
|
|
| Amnesia | 3 | 1 |
| Impaired concentration | 2 | 0 |
| Confusion | 5 | 1 |
| Hallucination | 5 | 1 |
| Somnolence | 40 | 6 |
| Yawning | 3 | 0 |
| Reproductive male |
|
|
| Impotence | 3 | 1 |
| Resistance mechanism |
|
|
| Viral Infection | 11 | 3 |
| Respiratory system |
|
|
| Bronchitis | 3 | 1 |
| Dyspnea | 3 | 0 |
| Pharyngitis | 6 | 4 |
| Rhinitis | 4 | 3 |
| Sinusitis | 4 | 3 |
| Urinary system |
|
|
| Urinary tract
infection | 5 | 4 |
| Vascular extracardiac |
|
|
| Peripheral ischemia | 3 | 0 |
| Vision |
|
|
| Eye abnormality | 3 | 1 |
| Abnormal vision | 6 | 3 |
| Xerophthalmia | 2 | 0 |
*Patients may have reported multiple adverse experiences
during the study or at discontinuation; thus, patients may be included in more
than one category.
Other events reported by 1% or more of early Parkinson's disease (without
L-dopa) patients treated with ropinirole hydrochloride, but that were equally or
more frequent in the placebo group, were: headache, upper respiratory infection,
insomnia, arthralgia, tremor, back pain, anxiety, dyskinesias, aggravated
Parkinsonism, depression, falls, myalgia, leg cramps, paresthesias, nervousness,
diarrhea, arthritis, hot flushes, weight loss, rash, cough, hyperglycemia,
muscle spasm, arthrosis, abnormal dreams, dystonia, increased salivation,
bradycardia, gout, basal cell carcinoma, gingivitis, hematuria, and rigors.
Among the treatment-emergent adverse events in patients treated with
ropinirole hydrochloride, hallucinations appear to be dose related.
The incidence of adverse events was not materially different between women
and men.
Advanced Parkinson's Disease (With L-dopa)
The most commonly observed adverse events (>5%), in the
double-blind, placebo-controlled advanced Parkinson's disease (with L-dopa)
trials associated with the use of ropinirole hydrochloride (n = 208) as an
adjunct to L-dopa not seen at an equivalent frequency among the placebo-treated
patients (n = 120) were, in order of decreasing incidence: dyskinesias, nausea,
dizziness, aggravated Parkinsonism, somnolence, headache, insomnia, injury,
hallucinations, falls, abdominal pain, upper respiratory infection, confusion,
increased sweating, vomiting, viral infection, increased drug level, arthralgia,
tremor, anxiety, urinary tract infection, constipation, dry mouth, pain,
hypokinesia, and paresthesia.
Approximately 24% of 208 patients who received ropinirole hydrochloride in
the double-blind, placebo-controlled advanced Parkinson's disease (with L-dopa)
trials discontinued treatment due to adverse events compared to 18% of 120
patients who received placebo. The events most commonly (≥1%) causing
discontinuation of treatment by patients treated with ropinirole hydrochloride
were: dizziness (2.9%), dyskinesias (2.4%), vomiting (2.4%), confusion (2.4%),
nausea (1.9%), hallucinations (1.9%), anxiety (1.9%), and increased sweating
(1.4%). Of these, hallucinations and dyskinesias appear to be dose
related.
Adverse Event Incidence in Controlled Clinical
Studies
Table 3 lists treatment-emergent adverse events that occurred in
≥2% of patients with advanced Parkinson's disease (with L-dopa) treated with
ropinirole hydrochloride who participated in the double-blind,
placebo-controlled studies and were numerically more common in the group treated
with ropinirole. In these studies, either ropinirole hydrochloride or placebo
was used as an adjunct to L-dopa. Adverse events were usually mild or moderate
in intensity.
The prescriber should be aware that these figures cannot be used to predict
the incidence of adverse events in the course of usual medical practice where
patient characteristics and other factors differ from those that prevailed in
the clinical studies. Similarly, the cited frequencies cannot be compared with
figures obtained from other clinical investigations involving different
treatments, uses, and investigators. However, the cited figures do provide the
prescribing physician with some basis for estimating the relative contribution
of drug and non-drug factors to the adverse events incidence rate in the
population studied.
Table 3. Treatment-Emergent Adverse Event * Incidence in Double-Blind, Placebo-Controlled
Advanced Parkinson's Disease (With L-dopa) Trials (Events ≥2% of Patients
Treated With Ropinirole and Numerically More Frequent Than the Placebo Group)
| Adverse Experience | Ropinirole (n = 208) (%) | Placebo (n=
120) (%) |
| Autonomic nervous
system |
|
|
| Dry mouth | 5 | 1 |
| Increased sweating | 7 | 2 |
| Body as a whole |
|
|
| Increased drug level | 7 | 3 |
| Pain | 5 | 3 |
| Cardiovascular general |
|
|
| Hypotension | 2 | 1 |
| Syncope | 3 | 2 |
| Central/peripheral nervous
system |
|
|
| Dizziness | 26 | 16 |
| Dyskinesia | 34 | 13 |
| Falls | 10 | 7 |
| Headache | 17 | 12 |
| Hypokinesia | 5 | 4 |
| Paresis | 3 | 0 |
| Paresthesia | 5 | 3 |
| Tremor | 6 | 3 |
| Gastrointestinal system |
|
|
| Abdominal pain | 9 | 8 |
| Constipation | 6 | 3 |
| Diarrhea | 5 | 3 |
| Dysphagia | 2 | 1 |
| Flatulence | 2 | 1 |
| Nausea | 30 | 18 |
| Increased saliva | 2 | 1 |
| Vomiting | 7 | 4 |
| Metabolic/nutritional |
|
|
| Weight decrease | 2 | 1 |
| Musculoskeletal system |
|
|
| Arthralgia | 7 | 5 |
| Arthritis | 3 | 1 |
| Psychiatric |
|
|
| Amnesia | 5 | 1 |
| Anxiety | 6 | 3 |
| Confusion | 9 | 2 |
| Abnormal dreaming | 3 | 2 |
| Hallucinations | 10 | 4 |
| Nervousness | 5 | 3 |
| Somnolence | 20 | 8 |
| Red blood cell |
|
|
| Anemia | 2 | 0 |
| Resistance mechanism |
|
|
| Upper respiratory
mechanism | 9 | 8 |
| Respiratory system |
|
|
| Dyspnea | 3 | 2 |
| Urinary system |
|
|
| Pyuria | 2 | 1 |
| Urinary incontinence | 2 | 1 |
| Urinary tract
infection | 6 | 3 |
| Vision |
|
|
| Diplopia | 2 | 1 |
*Patients may have reported multiple adverse experiences during the study or at discontinuation; thus; patients may be included in more than one category.
Other events reported by 1% or more of patients treated with both ropinirole
hydrochloride and L-dopa, but equally or more frequent in the placebo/ L-dopa
group, were: myocardial infarction, orthostatic symptoms, virus infections,
asthenia, dyspepsia, myalgia, back pain, depression, leg cramps, fatigue,
rhinitis, chest pain, hematuria, vertigo, tinnitus, leg edema, hot flushes,
abnormal gait, hyperkinesia, and pharyngitis.
Among the treatment-emergent adverse events in patients treated with
ropinirole hydrochloride, hallucinations and dyskinesias appear to be dose
related.
Restless Legs Syndrome
The most commonly observed adverse events (>5%) in the 12 week
double-blind, placebo-controlled trials in the treatment of Restless Legs
Syndrome with ropinirole hydrochloride (n = 496) and at least twice the rate for
placebo-treated patients (n = 500) were, in order of decreasing incidence:
nausea, somnolence, vomiting, dizziness, and fatigue (see Table 4). Occurrences of
nausea in clinical trials were generally mild to moderate in intensity (see also
DOSAGE AND
ADMINISTRATION: General Dosing Considerations).
Approximately 5% of 496 patients treated with ropinirole hydrochloride who
participated in the double-blind, placebo-controlled trials in the treatment of
RLS discontinued treatment due to adverse events compared to 4% of 500 patients
who received placebo. The adverse events most commonly causing discontinuation
of treatment by patients treated with ropinirole hydrochloride were: nausea
(1.6%), dizziness (0.8 %), and headache (0.8%).
Adverse Event Incidence in Controlled Clinical
Studies
Table 4 lists treatment-emergent adverse events that occurred in
≥2% of patients with RLS treated with ropinirole hydrochloride participating in
the 12 week double-blind, placebo-controlled studies and were numerically more
common in the group treated with ropinirole hydrochloride.
The prescriber should be aware that these figures cannot be used to predict
the incidence of adverse events in the course of usual medical practice where
patient characteristics and other factors differ from those that prevailed in
the clinical studies. Similarly, the cited frequencies cannot be compared with
figures obtained from other clinical investigations involving different
treatments, uses, and investigators. However, the cited figures do provide the
prescribing physician with some basis for estimating the relative contribution
of drug and non-drug factors to the adverse-events incidence rate in the
population studied.
Table 4. Treatment-Emergent Adverse Event Incidence in Double-Blind,
Placebo-Controlled RLS Trials (Events ≥2% of Patients Treated With Ropinirole
and Numerically More Frequent Than the Placebo Group)
| Adverse Experience | Ropinirole N = 496 (%) | Placebo N =
500 (%) |
| Ear and labyrinth
disorders |
|
|
| Vertigo | 2 | 1 |
| Gastrointestinal disorders |
|
|
| Nausea | 40 | 8 |
| Vomiting | 11 | 2 |
| Diarrhea | 5 | 3 |
| Dyspepsia | 4 | 3 |
| Dry mouth | 3 | 2 |
| Abdominal pain upper | 3 | 1 |
| General disorders and administration
site conditions |
|
|
| Fatigue | 8 | 4 |
| Edema peripheral | 2 | 1 |
| Infections and infestations |
|
|
| Nasopharyngitis | 9 | 8 |
| Influenza | 3 | 2 |
| Musculoskeletal and connective tissue
disorders |
|
|
| Arthralgia | 4 | 3 |
| Muscle cramps | 3 | 2 |
| Pain in extremity | 3 | 2 |
| Nervous system disorders |
|
|
| Somnolence | 12 | 6 |
| Dizziness | 11 | 5 |
| Paresthesia | 3 | 1 |
| Respiratory, thoracic, and
mediastinal disorders |
|
|
| Cough | 3 | 2 |
| Nasal congestion | 2 | 1 |
| Skin and subcutaneous tissue
disorders |
|
|
| Hyperhidrosis | 3 | 1 |
Other events reported by 2% or more of patients treated with ropinirole
hydrochloride, but equally or more frequent in the placebo group, were headache,
insomnia, restless legs syndrome, upper respiratory tract infection, back pain,
and sinusitis.
Other Adverse Events Observed During All Phase 2/3
Clinical Trials for Parkinson's Disease
Ropinirole hydrochloride has been administered to 1,599
individuals in clinical trials. During these trials, all adverse events were
recorded by the clinical investigators using terminology of their own choosing.
To provide a meaningful estimate of the proportion of individuals having adverse
events, similar types of events were grouped into a smaller number of
standardized categories using modified WHOART dictionary terminology. These
categories are used in the listing below. The frequencies presented represent
the proportion of the 1,599 individuals exposed to ropinirole hydrochloride who
experienced events of the type cited on at least one occasion while receiving
ropinirole hydrochloride. All reported events that occurred at least twice (or
once for serious or potentially serious events), except those already listed
above, trivial events, and terms too vague to be meaningful, are included
without regard to determination of a causal relationship to ropinirole
hydrochloride, except that events very unlikely to be drug-related have been
deleted.
Events are further classified within body system categories and enumerated in
order of decreasing frequency using the following definitions: frequent adverse
events are defined as those occurring in at least 1/100 patients and infrequent
adverse events are those occurring in 1/100 to 1/1,000 patients and rare events
are those occurring in fewer than 1/1,000 patients.
Body as a Whole: Infrequent: Cellulitis, peripheral edema, fever,
influenza-like symptoms, enlarged abdomen, precordial chest pain, and
generalized edema. Rare: Ascites.
Cardiovascular: Infrequent: Cardiac failure, bradycardia, tachycardia,
supraventricular tachycardia, angina pectoris, bundle branch block, cardiac
arrest, cardiomegaly, aneurysm, mitral insufficiency. Rare:
Ventricular tachycardia.
Central/Peripheral Nervous System:
Frequent: Neuralgia. Infrequent: Involuntary muscle contractions, hypertonia,
dysphonia, abnormal coordination, extrapyramidal disorder, migraine,
choreoathetosis, coma, stupor, aphasia, convulsions, hypotonia, peripheral
neuropathy, paralysis. Rare: Grand mal convulsions,
hemiparesis, hemiplegia.
Endocrine: Infrequent: Hypothyroidism, gynecomastia, hyperthyroidism.
Rare: Goiter, SIADH.
Gastrointestinal: Infrequent: Increased hepatic enzymes, bilirubinemia,
cholecystitis, cholelithiasis colitis, dysphagia, periodontitis, fecal
incontinence, gastroesophageal reflux, hemorrhoids, toothache, eructation,
gastritis, esophagitis, hiccups, diverticulitis, duodenal ulcer, gastric ulcer,
melena, duodenitis, gastrointestinal hemorrhage, glossitis, rectal hemorrhage,
pancreatitis, stomatitis and ulcerative stomatitis, tongue edema. Rare: Biliary pain, hemorrhagic gastritis, hematemesis,
salivary duct obstruction.
Hematologic: Infrequent: Purpura, thrombocytopenia, hematoma, Vitamin
B12 deficiency, hypochromic anemia, eosinophilia,
leukocytosis, leukopenia, lymphocytosis, lymphopenia, lymphedema.
Metabolic/Nutritional:
Frequent: Increased BUN. Infrequent: Hypoglycemia, increased alkaline phosphatase,
increased LDH, weight increase, hyperphosphatemia, hyperuricemia, diabetes
mellitus, glycosuria, hypokalemia, hypercholesterolemia, hyperkalemia, acidosis,
hyponatremia, thirst, increased CPK, dehydration. Rare:
Hypochloremia.
Musculoskeletal: Infrequent: Aggravated arthritis, tendonitis, osteoporosis,
bursitis, polymyalgia rheumatica, muscle weakness, skeletal pain, torticollis.
Rare: Dupuytren's contracture requiring surgery.
Neoplasm: Infrequent: Malignant breast neoplasm. Rare: Bladder carcinoma, benign brain neoplasm, esophageal
carcinoma, malignant laryngeal neoplasm, lipoma, rectal carcinoma, uterine
neoplasm.
Psychiatric: Infrequent: Increased libido, agitation, apathy, impaired
concentration, depersonalization, paranoid reaction, personality disorder,
euphoria, delirium, dementia, delusion, emotional lability, decreased libido,
manic reaction, somnambulism, aggressive reaction, neurosis. Rare: Suicide attempt.
Genitourinary: Infrequent: Amenorrhea, vaginal hemorrhage, penile
disorder, prostatic disorder, balanoposthitis, epididymitis, perineal pain,
dysuria, micturition frequency, albuminuria, nocturia, polyuria, renal calculus.
Rare: Breast enlargement, mastitis, uterine
hemorrhage, ejaculation disorder, Peyronie's disease, pyelonephritis, acute
renal failure, uremia.
Resistance Mechanism:
Infrequent: Herpes zoster, otitis
media, sepsis, abscess, herpes simplex, fungal infection, genital
moniliasis.
Respiratory: Infrequent: Asthma, epistaxis, laryngitis, pleurisy,
pulmonary edema.
Skin/Appendage: Infrequent: Pruritus, dermatitis, eczema, skin ulceration,
alopecia, skin hypertrophy, skin discoloration, urticaria, fungal dermatitis,
furunculosis, hyperkeratosis, photosensitivity reaction, psoriasis,
maculopapular rash, psoriaform rash, seborrhea.
Special Senses: Infrequent: Tinnitus, earache, decreased hearing, abnormal
lacrimation, conjunctivitis, blepharitis, glaucoma, abnormal accommodation,
blepharospasm, eye pain, photophobia. Rare:
Scotoma.
Vascular Extracardiac:
Infrequent: Varicose veins, phlebitis,
peripheral gangrene. Rare: Limb embolism, pulmonary
embolism, gangrene, subarachnoid hemorrhage, deep thrombophlebitis, leg
thrombophlebitis, thrombosis.
Falling Asleep During Activities of Daily Living
Patients treated with ropinirole hydrochloride have reported
falling asleep while engaged in activities of daily living, including operation
of a motor vehicle which sometimes resulted in accidents (see bolded WARNING).
Other Adverse Events Observed During Phase 2/3
Clinical Trials for RLS
Ropinirole hydrochloride has been administered to 911 individuals
in clinical trials. During these trials, all adverse events were recorded by the
clinical investigators using terminology of their own choosing. To provide a
meaningful estimate of the proportion of individuals having adverse events,
similar types of events were grouped into a smaller number of standardized
categories using MedDRA dictionary terminology. These categories are used in the
listing below. The frequencies presented represent the proportion of the 911
individuals exposed to ropinirole hydrochloride who experienced events of the
type cited on at least one occasion while receiving ropinirole hydrochloride.
All reported events that occurred at least twice (or once for serious or
potentially serious events), except those already listed, trivial events, and
terms too vague to be meaningful, are included without regard to determination
of a causal relationship to ropinirole hydrochloride, except that events very
unlikely to be drug-related have been deleted.
Events are further classified within body system categories and enumerated in
order of decreasing frequency using the following definitions: frequent adverse
events are defined as those occurring in at least 1/100 patients and infrequent
adverse events are those occurring in 1/100 to 1/1,000 patients.
Blood and Lymphatic System Disorder:
Infrequent: Anemia,
lymphadenopathy.
Cardiac Disorders: Frequent: Palpitations. Infrequent:
Acute coronary syndrome, angina pectoris, angina unstable, bradycardia,
cardiac failure, cardiovascular disorder, coronary artery disease, myocardial
infarction, sick sinus syndrome, tachycardia.
Congenital, Familial, and Genetic
Disorders: Infrequent: Pigmented
nevus.
Ear and Labyrinth Disorder:
Infrequent: Ear pain, middle ear
effusion, tinnitus.
Endocrine Disorders: Infrequent: Goiter, hypothyroidism.
Eye Disorders: Infrequent: Blepharitis, conjunctival hemorrhage,
conjunctivitis, eye irritation, eye pain, keratoconjunctivitis sicca, vision
blurred, visual acuity reduced, visual disturbance.
Gastrointestinal Disorders:
Frequent: Abdominal pain, constipation,
gastroesophageal reflux disease, stomach discomfort, toothache. Infrequent: Abdominal adhesions, abdominal discomfort,
abdominal distension, abdominal pain lower, duodenal ulcer, dysphagia,
eructation, flatulence, gastric disorder, gastric hemorrhage, gastric polyps,
gastric ulcer, gastritis, gastrointestinal pain, hematemesis, hemorrhoids,
hiatus hernia, intestinal obstruction, irritable bowel syndrome, loose stools,
mouth ulceration, pancreatitis acute, peptic ulcer, rectal hemorrhage, reflux
esophagitis.
General Disorders and Administration
Site Conditions: Frequent: Asthenia,
chest pain, influenza-like illness, rigors. Infrequent:
Chest discomfort, feeling cold, feeling hot, hunger, lethargy, malaise,
edema, pain, pyrexia.
Hepatobiliary Disorders:
Infrequent: Cholecystitis,
cholelithiasis, ischemic hepatitis.
Immune System Disorders:
Infrequent: Hypersensitivity.
Infections and Infestations:
Frequent: Bronchitis, gastroenteritis,
gastroenteritis viral, lower respiratory tract infection, rhinitis, tooth
abscess, urinary tract infection. Infrequent:
Appendicitis, bacterial infection, bladder infection, bronchitis acute,
candidiasis, cellulitis, cystitis, diarrhea infectious, diverticulitis, ear
infection, folliculitis, fungal infection, gastrointestinal infection, herpes
simplex, infected cyst, laryngitis, localized infection, mastitis, otitis
externa, otitis media, pharyngitis, pneumonia, postoperative infection,
respiratory tract infection, tonsillitis, tooth infection, vaginal candidiasis,
vaginal infection, vaginal mycosis, viral infection,
viral upper respiratory tract infection, wound infection.
Injury, Poisoning, and Procedural
Complications: Infrequent: Concussion,
lower limb fracture, post procedural hemorrhage, road traffic accident.
Investigations: Infrequent: Blood cholesterol increased, blood iron
decreased, blood pressure increased, blood urine present, hemoglobin decreased,
heart rate increased, protein urine present, weight decreased, weight
increased.
Metabolism and Nutrition Disorders:
Infrequent: Anorexia, decreased
appetite, diabetes mellitus non-insulin-dependent, fluid retention, gout,
hypercholesterolemia.
Musculoskeletal and Connective Tissue
Disorders: Frequent: Muscle spasms,
musculoskeletal stiffness, myalgia, neck pain, osteoarthritis, tendonitis. Infrequent: Arthritis, aseptic necrosis bone, bone pain,
bone spur, bursitis, groin pain, intervertebral disc degeneration,
intervertebral disc protrusion, joint stiffness, joint swelling, localized
osteoarthritis, monoarthritis, muscle contracture, muscle tightness, muscle
twitching, osteoporosis, rotator cuff syndrome, sacroiliitis, synovitis.
Neoplasms Benign, Malignant, and
Unspecified: Infrequent: Anaplastic
thyroid cancer, angiomyolipoma, basal cell carcinoma, breast cancer, gastric
cancer, gastrointestinal stromal tumor, malignant melanoma, prostate cancer,
skin papilloma, squamous cell carcinoma, uterine leiomyoma.
Nervous System Disorders:
Frequent: Hypoesthesia, migraine. Infrequent: Amnesia, aphasia, ataxia, balance disorder,
benign intracranial hypertension, burning sensation, carpal tunnel syndrome,
disturbance in attention, dizziness postural, dysgeusia, dyskinesia, head
discomfort, hyperesthesia, hypersomnia, lethargy, loss of consciousness, memory
impairment, migraine with aura, migraine without aura, neuralgia, sciatica,
sinus headache, sleep apnea syndrome, syncope vasovagal, tension headache,
transient ischemic attack, tremor.
Psychiatric Disorders:
Frequent: Anxiety, depression,
irritability, sleep disorder. Infrequent: Abnormal
dreams, agitation, bruxism, confusional state, depressed mood, disorientation,
early morning awakening, libido decreased, loss of libido, mood swings,
nervousness, nightmare, panic attack, stress symptoms, tension.
Renal and Urinary Disorders:
Infrequent: Dysuria, hematuria,
hypertonic bladder, micturition disorder, nephrolithiasis, nocturia,
pollakiuria, proteinuria, urinary retention.
Reproductive System and Breast
Disorders: Frequent: Erectile
dysfunction. Infrequent: Breast cyst, dysmenorrhea,
menorrhagia, pelvic peritoneal adhesions, postmenopausal hemorrhage,
premenstrual syndrome, prostatitis.
Respiratory, Thoracic and Mediastinal
Disorders: Frequent: Asthma,
pharyngolaryngeal pain. Infrequent: Dry throat,
dyspnea, epistaxis, hemoptysis, hoarseness, interstitial lung disease, nasal
mucosal disorder, nasal polyps, respiratory tract congestion, rhinorrhea, sinus
congestion, sneezing, wheezing, yawning.
Skin and Subcutaneous Tissue Disorders:
Frequent: Night sweats, rash. Infrequent: Acne, actinic keratosis, alopecia, cold sweat,
dermatitis, dermatitis allergic, dermatitis contact, eczema, exanthem, face
edema, photosensitivity reaction, pruritus, psoriasis, rash pruritic, skin
lesion, urticaria.
Postmarketing Reports
Psychiatric Disorders:
Impulse control symptoms, pathological gambling, increased libido
including hypersexuality.
Vascular Disorders: Frequent: Hot flush, hypertension, hypotension. Infrequent: Atherosclerosis, circulatory collapse,
flushing, hematoma, thrombosis, varicose vein.